PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Blood. Author manuscript; available in PMC 2010 April 28.
Published in final edited form as:
PMCID: PMC2860856
NIHMSID: NIHMS187462

Role of tissue factor and protease-activated receptors in a mouse model of endotoxemia

Abstract

Sepsis is associated with a systemic activation of coagulation and an excessive inflammatory response. Anticoagulants have been shown to inhibit both coagulation and inflammation in sepsis. In this study, we used both genetic and pharmacologic approaches to analyze the role of tissue factor and protease-activated receptors in coagulation and inflammation in a mouse endotoxemia model. We used mice expressing low levels of the procoagulant molecule, tissue factor (TF), to analyze the effects of TF deficiency either in all tissues or selectively in hematopoietic cells. Low TF mice had reduced coagulation, inflammation, and mortality compared with control mice. Similarly, a deficiency of TF expression by hematopoietic cells reduced lipopolysaccharide (LPS)–induced coagulation, inflammation, and mortality. Inhibition of the downstream coagulation protease, thrombin, reduced fibrin deposition and prolonged survival without affecting inflammation. Deficiency of either protease activated receptor-1 (PAR-1) or protease activated receptor-2 (PAR-2) alone did not affect inflammation or survival. However, a combination of thrombin inhibition and PAR-2 deficiency reduced inflammation and mortality. These data demonstrate that hematopoietic cells are the major pathologic site of TF expression during endotoxemia and suggest that multiple protease-activated receptors mediate crosstalk between coagulation and inflammation.

Introduction

Sepsis is induced by a systemic infection, mostly by Gram-negative bacteria, and is associated with activation of coagulation and inflammation.1 In sepsis, an excessive stimulation of the host immune system by lipopolysaccharide (LPS) results in high levels of inflammatory cytokines in the circulation. However, clinical trials that targeted specific inflammatory mediators have not been successful.2 Despite extensive research, sepsis remains a major cause of death in intensive care units, with mortality rates between 30% and 70%.2 Three natural anticoagulants, tissue factor pathway inhibitor-1 (TFPI-1), antithrombin-III (AT-III), and activated protein C (APC), have been shown to have both anticoagulant and antiinflammatory properties in different animal models of sepsis.35 All 3 anticoagulants showed positive results in phase 2 clinical trials for sepsis, although only human recombinant APC was protective in a phase 3 clinical trial.2,69

LPS induction of the procoagulant molecule, tissue factor (TF), within the vasculature causes systemic activation of coagulation and disseminated intravascular coagulation.10 In animal models of sepsis, TF is expressed by circulating monocytes and by splenic microvascular endothelial cells but not by endothelial cells in other vascular beds.1113 Intravascular fibrin deposition contributes to multiple organ failure and mortality in different animal models of endotoxemia and human sepsis.10 In endotoxemic rabbits, selective inhibition of thrombin with hirudin decreased fibrin deposition and decreased mortality.14 Moreover, endotoxemicAT-III+/ and PC+/ heterozygous mice exhibited increased fibrin deposition and mortality compared with wild-type (WT) controls, presumably due to reduced levels of the anticoagulants.15,16

In a lethal baboon model of Escherichia coli–induced sepsis, inhibition of the TF–factor VIIa (FVIIa) complex with either an inhibitory anti-TF monoclonal antibody, active site-inhibited FVIIa (FVIIai), or TFPI-1 decreased coagulation and prevented death.3,17,18 Importantly, FVIIai and TFPI-1 reduced the expression of the inflammatory mediators interleukin-6 (IL-6) and IL-8 at later times (more than 4 hours after administration of E coli) but did not affect tumor necrosis factor-α (TNF-α) expression,3,18 indicating that IL-6 expression can be used to monitor crosstalk between coagulation and inflammation. In contrast, FXai blocked coagulation in septic baboons without reducing mortality.19 These studies suggest that the TF-FVIIa complex mediates crosstalk between coagulation and inflammation in sepsis.

Studies on the crosstalk between coagulation and inflammation have focused on the protease activated receptor (PAR) family, which comprises 4 members, PAR-1 to PAR-4.20,21 Several studies using cultured cells have shown that the TF-FVIIa and TF-FVIIa-FXa complexes, as well as FXa, can activate PAR-2.2224 In mice, thrombin activates both PAR-1 and PAR-4 on vascular cells and a PAR-3–PAR-4 complex on platelets.20,21 PAR-1 can also be activated by FXa in vitro.24,25 LPS and inflammatory cytokines induce PAR-2 expression on endothelial cells, and IL-1 induces both PAR-2 and PAR-4 in human coronary artery tissue.26,27 In vivo studies have shown that PAR-2 plays a role in leukocyte rolling and in mediating chronic inflammation associated with arthritis.28,29 Thrombin activation of PAR-1 has been shown to induce the expression of proinflammatory cytokines and chemokines in vitro and to contribute to renal inflammation in vivo.20,30 In addition, LPS and TNF-α induction of IL-6 expression by cultured endothelial cells is enhanced by activation of PAR-1 and PAR-2.31 Taken together, these studies suggest that activation of PARs by coagulation proteases may contribute to inflammation in endotoxemia and sepsis.

In this study, we used genetic and pharmacologic approaches to analyze the role of TF and PARs in coagulation and inflammation in a mouse model of endotoxemia. In addition, we analyzed the role of hematopoietic cell TF expression in endotoxemia by reconstituting wild-type mice with bone marrow from low TF mice. Our results indicate that hematopoietic cells are the major site of pathologic TF expression during endotoxemia and that PARs mediate the crosstalk between coagulation and inflammation.

Materials and methods

Mice

All studies were approved by The Scripps Research Institute Animal Care and Use Committee and comply with National Institutes of Health guidelines. Low TF mice expressing very low levels of human (h) TF (approximately 1% relative to mouse [m] TF) and completely lacking murine TF (mTF−/−/hTF+) and heterozygous littermate controls (mTF+/−/hTF+) were generated as described previously.32 The generation of PAR-1/ and PAR-2/ mice has been described.33,34 All genetically modified mice were backcrossed for at least 5 generations with C57BL/6 mice. Mice were used for experiments between 2 and 3 months of age.

Model of endotoxemia

We employed a mouse model of endotoxemia that consists of intraperitoneal injection of a high dose of LPS (10 mg/kg) (E coli serotype O111:B4; Sigma Chemical, St Louis, MO).35 Littermate controls were used in all experiments. In the bone marrow transplantation experiments, we used a lower dose of LPS (5 mg/kg) due to increased sensitivity of the mice to LPS.

Hirudin treatment

Hirudin specifically blocks thrombin activity through competitive inhibition of its catalytic site.36 We used recombinant hirudin (lepirudin; Hoechst Marion Roussel, Kansas City, MO). The dose and frequency of injections was based on Ehrlich et al’s previous experience with the use of hirudin in rabbits and measuring the activated partial thromboplastin time (APTT) of plasma samples from mice injected with hirudin.37 APTTs were measured using the Automated APTT reagent (bioMérieux, Durham, NC) and a Start 4 clot analyzer (Diagnostica Stago, Parsippany, NJ). After a single intraperitoneal injection of recombinant hirudin (1 mg/kg), the APTT was increased from a baseline of 26.4 ± 1.4 seconds (mean ± SD; n = 4) to 56.1 ± 7.0 seconds and 52.0 ± 8.1 seconds at 30 and 60 minutes, respectively, before returning to baseline levels at 4 hours. For the experiments, 4 injections of hirudin were administered 30 minutes before injection of LPS and 30 minutes, 2 hours, and 4 hours after injection of LPS. Mice in the control group received saline.

Ancrod treatment

Ancrod cleaves only the A-chains of fibrinogen, producing soluble degradation products that are removed from the circulation.38 The dose of ancrod was based on our experience with rabbits and a previous study with mice.37,39 Mice received ancrod (Sigma Chemical) in 4 bolus injections (1 unit in 0.2 mL of saline each) via the retro-orbital sinus, starting 16 hours before LPS challenge (−16 hours, −8 hours, 0 hours, and +8 hours). Control mice were injected with saline.

Measurement of thrombin–antithrombin-III (TAT) and fibrinogen

Blood was drawn from the inferior vena cava (IVC) into syringes containing 3.2% sodium citrate (final ratio, 10:1). Levels of thrombin–antithrombin-III (TAT) complex in the plasma were determined using a commercial enzyme-linked immunosorbent assay (ELISA) (Enzygnost TAT micro; Dade Behring, Marburg, Germany). Fibrinogen levels were determined by the Clauss method using the Sigma Diagnostics Fibrinogen Kit (Sigma Chemical).

Measurement of cytokines

Blood samples (0.1 mL) were collected from the retro-orbital sinus. Plasma concentrations of TNF-α and IL-6 were measured using commercial ELISA kits (R&D Systems, Minneapolis, MN).

Bone marrow transplantation

Bone marrow of recipient mice was ablated with a single dose of radiation (13 Gy [1300 rad]) from a cesium 137 irradiator (Gammacell 40; Atomic Energy of Canada, Mississauga, ON, Canada). Recipient mice were injected with 2 × 106 bone marrow cells via the retro-orbital sinus. Mice were allowed to recover for 6 weeks after transplantation before LPS injection. Blood samples were collected from WT mice receiving bone marrow from either low TF mice or littermate mTF+/−/hTF+ control mice and used to determine platelet counts, red cell counts, hematocrit, and hemoglobin levels (Laboratory Corporation of America, San Diego, CA).

Genotyping of DNA from bone marrow recipient mice

Blood was collected from the IVC. The WT mouse TF allele was detected by polymerase chain reaction (PCR) using a forward primer located 1097 to 1070 base pair (bp) upstream of exon 1 and a reverse primer located 563 to 539 bp upstream of exon 1 (numbering from 787).

Immunohistochemistry and Western blotting

Mice were perfused through the left ventricle with phosphate-buffered saline (PBS) to remove fibrinogen from the blood vessels. Tissues were rapidly removed, fixed in 10% zinc formalin solution, and embedded in paraffin. Tissue sections were incubated overnight with a rabbit antimouse fibrinogen antibody (1:5000) (Dako, Carpinteria, CA), which was detected using the Rabbit Vectastatin Elite ABC kit (Vector Laboratories, Burlingame, CA). Antigen-antibody complexes were visualized using 3′, 3′-diamino benzidine (Vector Laboratories). The amount of cross-linked fibrin present in livers was determined by Western blotting using a mouse antihuman β-chain monoclonal antibody (59D8) (1:500) that binds to fibrin but not fibrinogen.40 A pan-anticadherin antibody (Sigma Chemical) was used to monitor protein loading.

Data analysis

Cytokine, TAT, and fibrinogen levels are presented as mean ± standard error (SE). Statistical analysis was performed using an unpaired Student t test. The survival rate of the groups was analyzed by log-rank test. Differences were determined to be statistically significant at P values less than .05.

Results

Low TF mice exhibit decreased LPS-induced coagulation, inflammation, and mortality

In this study, we determined whether a genetic deficiency in TF that dramatically reduces TF expression in all tissues would reduce mortality of the mice in a model of endotoxemia. We measured LPS-induced activation of coagulation by monitoring levels of TAT complex. Administration of LPS increased TAT levels in WT mice in a time-dependent manner from a baseline of 3.5 ± 1.2 ng/mL (mean ± SD; n = 4) to 11.2 ± 3.2 ng/mL at 2 hours, 21.2 ± 6.9 ng/mL at 4 hours, 45.5 ± 9.2 ng/mL at 8 hours, and 31.5 ± 12.1 ng/mL at 12 hours. We found that LPS induction of TAT complex levels was significantly reduced in low TF mice compared with littermate mTF+/−/hTF+ control mice (Figure 1A), indicating that activation of coagulation is significantly attenuated in these mice. Importantly, low TF mice exhibited prolonged survival and decreased mortality compared with control mice (Figure 1B). We measured LPS induction of TNF-α and IL-6 to determine whether TF deficiency was associated with reduced inflammation. TF deficiency did not affect LPS-induced TNF-α expression but was associated with a significant reduction in IL-6 expression at later times (Figure 1C–D). These results indicate that TF deficiency in all tissues reduces coagulation and inflammation and decreases mortality in this model of endotoxemia.

Figure 1
Role of TF in LPS-induced lethality

Role of hematopoietic cell TF in LPS-induced lethality

We analyzed the role of hematopoietic cell–derived TF expression in LPS-induced lethality by transplanting, into WT mice, bone marrow from either low TF mice or littermate mTF+/−hTF+ control mice. PCR analysis of DNA from peripheral blood cells showed that irradiated recipient mice reconstituted with bone marrow from low TF mice had no detectable levels of the WT mTF allele (Figure 2A). A deficiency in TF expression by hematopoietic cells did not affect the composition of the peripheral blood cell population (not shown). LPS-induced TAT complex levels were significantly reduced in WT mice receiving bone marrow from low TF mice (Figure 2B). Importantly, WT mice reconstituted with bone marrow from low TF mice had significantly reduced mortality after LPS injection compared with WT reconstituted with bone marrow from control mice (Figure 2C). Finally, a reduction in TF expression by hematopoietic cells resulted in reduced levels of IL-6 expression compared with WT controls (Figure 2D), although these differences did not achieve statistical significance. These results indicate that hematopoietic cells are the major site of pathologic TF expression that contributes to LPS-induced coagulation, inflammation, and lethality.

Figure 2
Role of hematopoietic cell TF expression in LPS-induced lethality

Role of thrombin and fibrin in LPS-induced lethality

We used the selective thrombin inhibitor, hirudin, and the defibrinogenating agent, ancrod, to analyze the role of thrombin and fibrin deposition in this endotoxemia model.

Administration of hirudin reduced LPS induction of TAT complex levels compared with mice receiving saline (Figure 3A). Levels of TAT complex observed in endotoxemic mice treated with hirudin were similar to those observed in endotoxemic low TF mice. Hirudin significantly prolonged the survival time of mice (Figure 3B). However, hirudin treatment did not affect LPS induction of TNF-α and IL-6 expression (Figure 3C–D). Next, we analyzed the effect of hirudin on LPS-induced fibrin deposition. Hirudin treatment reduced LPS-induced fibrin deposition in the liver as determined by both immunohistochemical analysis and Western blotting (Figure 3E–F). To further examine the role of thrombin-dependent fibrin deposition in LPS-induced lethality, we used ancrod to deplete circulating fibrinogen in the mice. Administration of ancrod decreased fibrinogen levels from 5.9 ± 0.5 μM (1.99 ± 0.16 g/L) (mean ± SD; n = 3) to undetectable levels (less than 0.015 μM [0.05 g/L]; n = 3). Ancrod treatment significantly prolonged the survival of mice compared with that of control mice (Figure 3G). This result is similar to those observed using hirudin and strongly suggests that thrombin-dependent intravascular fibrin deposition contributes to death in this model of endotoxemia.

Figure 3
Effect of administration of hirudin and ancrod on endotoxemic mice

Role of PARs in LPS-induced inflammation and lethality

We used PAR-1−/− and PAR-2−/− mice to determine whether either PAR-1 or PAR-2 mediates the crosstalk between coagulation and inflammation and contributes to LPS-induced lethality. We found no difference in the survival of PAR-2−/− and PAR-2+/+ mice and no difference in the expression of TNF-α and IL-6 (Figure 4A–C). Similarly, we found that PAR-1 deficiency did not affect either survival or LPS-induced TNF-α and IL-6 expression (Figure 4D–F).

Figure 4
Role of PARs in LPS-induced lethality

We have shown that neither thrombin inhibition nor PAR-1 or PAR-2 deficiency alone affects LPS induction of IL-6 expression. We hypothesized that multiple PARs may mediate the crosstalk between coagulation and inflammation. Therefore, deficiency of a single PAR or hirudin inhibition of thrombin–PAR-1 and thrombin–PAR-4 signaling may not significantly affect inflammation. To test this hypothesis, we examined the effect of combining thrombin inhibition, which would reduce fibrin deposition and thrombin-dependent signaling, with PAR-2 deficiency. PAR-2−/− mice treated with hirudin showed a significantly prolonged survival time when compared with PAR-2+/+ mice treated with hirudin (Figure 5A). Importantly, in PAR-2−/− mice, hirudin treatment significantly reduced IL-6 expression compared with that in hirudin-treated PAR-2+/+ mice (Figure 5B). As seen previously in WT mice, there was no difference in either survival or IL-6 expression in endotoxemic PAR-2+/+ mice treated with saline or hirudin (Figure 5). These data suggest that multiple PARs mediate the crosstalk between coagulation and inflammation during endotoxemia.

Figure 5
Effect of combined hirudin treatment and PAR-2 deficiency

Discussion

In this study, we showed in a model of endotoxemia that low TF mice had reduced coagulation, reduced expression of IL-6, and decreased mortality compared with littermate mTF+/−/hTF+ control mice. These results are consistent with studies showing that inhibition of the TF-FVIIa complex in septic baboons reduced the expression of IL-6 and IL-8 and reduced mortality.3,17,18 Thus, the TF-FVIIa complex contributes to LPS-induced coagulation, inflammation, and mortality in different animal models of endotoxemia and sepsis. The TF-FVIIa complex can be inhibited by either TFPI-1, FVIIai, or anti-TF antibodies (Figure 6). The failure of the TFPI-1 phase 3 clinical trial for sepsis is disappointing.41 However, TFPI-1 is the least effective inhibitor of the 3 inhibitors of the TF-FVIIa complex because it requires the generation of FXa for the formation of the inhibitory quaternary complex.3 In contrast, FVIIai acts as a competitive inhibitor of FVII/FVIIa binding to TF, and the anti-TF antibodies used in these studies bind to the TF-FVIIa complex and inhibit substrate binding.4244 Therefore, FVIIai and anti-TF antibodies may prove to be more effective drugs than TFPI-1 in the treatment of inflammatory diseases where there is crosstalk between coagulation and inflammation. In the model shown in Figure 6, inhibition of the TF-FVIIa complex would reduce fibrin deposition, platelet activation, and all PAR-dependent signaling.

Figure 6
Coagulation proteases increase inflammation during endotoxemia via PARs

Monocytes are the primary hematopoietic cells that express TF in endotoxemic animals and humans.11 We found that TF deficiency in hematopoietic cells reduced LPS-induced activation of coagulation, IL-6 expression, and decreased mortality in a similar manner to that observed in low TF mice. However, the levels of TAT in WT mice with low TF bone marrow were not as low as those observed in endotoxemic low TF mice, and the reduction in LPSinduced IL-6 did not achieve statistical significance. This suggests that other vascular cells may contribute to the generation of thrombin and IL-6 expression during endotoxemia. Nevertheless, our results demonstrate that hematopoietic cells, presumably the monocyte population, are the major pathologic site of TF expression during endotoxemia. In endotoxemic animals there is a rapid decrease in the number of circulating leukocytes, which suggests that the majority of TF-positive monocytes will be present adhered to the endothelium.3,18 At this site, TF expression may contribute to both fibrin deposition and inflammation.

We found that hirudin inhibition of thrombin prolonged the survival of endotoxemic mice. This protection may be due to a reduction in thrombin-dependent fibrin deposition and platelet activation as well as a reduction in PAR-1 and PAR-4 signaling (Figure 6). However, neither thrombin inhibition nor PAR-1 deficiency reduced inflammation. In contrast, we showed that hirudin significantly inhibited LPS-induced activation of coagulation and fibrin deposition. In addition, we found that ancrod prolonged the survival of endotoxemic mice. These results suggest that hirudin protected endotoxemic mice primarily by reducing fibrin deposition, although we cannot exclude the possibility that hirudin inhibition of platelet activation as well as PAR-1 and PAR-4 signaling also contributed to the protection.

PAR-1 deficiency did not affect the survival of endotoxemic mice and the expression of IL-6. However, loss of PAR-1 may affect both protective and pathologic pathways. For instance, in endotoxemic rats, the endothelial cell protein C receptor was induced in a thrombin-dependent manner, presumably by activation of PAR-1 on endothelial cells.45 In addition, APC activation of PAR-1 may be protective in endotoxemia.46

What mediates the crosstalk between coagulation and inflammation? We found that PAR-1 or PAR-2 deficiency did not affect LPS-induced IL-6 expression or survival. In addition, inhibition of thrombin-dependent signaling did not reduce inflammation. These data suggested that there may be redundancy in the PAR signaling pathways. PAR-1, PAR-2, and PAR-4 may all contribute to the crosstalk. Therefore, we examined the combined effects of inhibition of thrombin-dependent signaling and PAR-2 deficiency to simultaneously inhibit multiple PAR-dependent pathways. Hirudintreated PAR-2−/− mice had significantly reduced IL-6 expression and showed additional protection in survival compared with hirudin-treated PAR-2+/+ mice. These data suggest that PAR-2 signaling as well as thrombin-dependent signaling, most likely via PAR-1 and/or PAR-4, contribute to LPS-induced IL-6 expression in endotoxemic mice. Therefore, inhibition of PAR-dependent signaling in combination with anticoagulants may be an effective strategy in the treatment of human sepsis.47,48

Acknowledgments

We thank M. Riewald for helpful discussions, M. Szeto for technical assistance, and C. Johnson for preparing the manuscript.

Supported by grant HL48872 from the National Institutes of Health.

References

1. Parrillo JE. Pathogenetic mechanisms of septic shock. N Engl J Med. 1993;328:1471–1477. [PubMed]
2. Riedemann NC, Guo RF, Ward PA. Novel strategies for the treatment of sepsis. Nat Med. 2003;9:517–524. [PubMed]
3. Creasey AA, Chang AC, Feigen L, Wun TC, Hinshaw LB. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J Clin Invest. 1993;91:2850–2856. [PMC free article] [PubMed]
4. Taylor FB, Jr, Emerson TE, Jr, Jordan R, Chang AK, Blick KE. Antithrombin-III prevents the lethal effects of Escherichia coli infusion in baboons. Circ Shock. 1998;26:227–235. [PubMed]
5. Taylor FB, Jr, Chang A, Esmon CT, D’Angelo A, Vigano-D’Angelo S, Blick KE. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest. 1987;79:918–925. [PMC free article] [PubMed]
6. Opal SM. Therapeutic rationale for antithrombin III in sepsis. Crit Care Med. 2000;28:S34–S37. [PubMed]
7. Abraham E, Reinhart K, Svoboda P, et al. Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study. Crit Care Med. 2001;29:2081–2089. [PubMed]
8. Abraham E. Tissue factor inhibition and clinical trial results of tissue factor pathway inhibitor in sepsis. Crit Care Med. 2000;28:S31–S33. [PubMed]
9. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001;344:699–709. [PubMed]
10. Levi M, Ten Cate H. Disseminated intravascular coagulation. N Engl J Med. 1999;341:586–592. [PubMed]
11. Morrissey JH, Drake TA. Procoagulant response of the endothelium and monocytes. In: Schlag G, Redl H, editors. Pathophysiology of Shock, Sepsis, and Organ Failure. New York, NY: Springer-Verlag; 1993. pp. 564–574.
12. Drake TA, Cheng J, Chang A, Taylor FB., Jr Expression of tissue factor, thrombomodulin, and E-selectin in baboons with lethal Escherichia coli sepsis. Am J Pathol. 1993;142:1–13. [PubMed]
13. Erlich JH, Fearns C, Mathison J, Ulevitch RJ, Mackman N. Lipopolysaccharide induction of tissue factor expression in rabbits. Infect Immun. 1999;67:2540–2546. [PMC free article] [PubMed]
14. Hermida J, Montes R, Paramo JA, Rocha E. Endotoxin-induced disseminated intravascular coagulation in rabbits: effect of recombinant hirudin on hemostatic parameters, fibrin deposits, and mortality. J Lab Clin Med. 1998;131:77–83. [PubMed]
15. Yanada M, Kojima T, Ishiguro K, et al. Impact of antithrombin deficiency in thrombogenesis: lipopolysaccharide and stress-induced thrombus formation in heterozygous antithrombin-deficient mice. Blood. 2002;99:2455–2458. [PubMed]
16. Levi M, Dorffler-Melly J, Reitsma P, et al. Aggravation of endotoxin-induced disseminated intravascular coagulation and cytokine activation in heterozygous protein-C-deficient mice. Blood. 2003;101:4823–4827. [PubMed]
17. Taylor FB, Jr, Chang A, Ruf W, et al. Lethal E. coli septic shock is prevented by blocking tissue factor with monoclonal antibody. Circ Shock. 1991;33:127–134. [PubMed]
18. Taylor F, Chang A, Peer G, Li A, Ezban M, Hedner U. Active site inhibited factor VIIa (DEGR VIIa) attenuates the coagulant and interleukin-6 and -8, but not tumor necrosis factor: responses of the baboon to LD100 Escherichia coli. Blood. 1998;91:1609–1615. [PubMed]
19. Taylor FB, Chang ACK, Peer GT, et al. DEGR-factor Xa blocks disseminated intravascular coagulation initiated by Escherichia coli without preventing shock or organ damage. Blood. 1991;78:364–368. [PubMed]
20. Coughlin SR. Thrombin signalling and protease-activated receptors. Nature. 2000;407:258–264. [PubMed]
21. Major CD, Santulli RJ, Derian CK, Andrade-Gordon P. Extracellular mediators in atherosclerosis and thrombosis: lessons from thrombin receptor knockout mice. Arterioscler Thromb Vasc Biol. 2003;23:931–939. [PubMed]
22. Camerer E, Huang W, Coughlin SR. Tissue factor-and factor X-dependent activation of protease-activated receptor 2 by factor VIIa. Proc Natl Acad Sci U S A. 2000;97:5255–5260. [PubMed]
23. Camerer E, Kataoka H, Kahn M, Lease K, Coughlin SR. Genetic evidence that protease-activated receptors mediate factor Xa signaling in endothelial cells. J Biol Chem. 2002;277:16081–16087. [PubMed]
24. Riewald M, Ruf W. Mechanistic coupling of protease signaling and initiation of coagulation by tissue factor. Proc Natl Acad Sci U S A. 2001;98:7742–7747. [PubMed]
25. Riewald M, Kravchenko V, Petrovan R, et al. Gene induction by coagulation factor Xa is mediated by activation of protease-activated receptor 1. Blood. 2001;97:3109–3116. [PubMed]
26. Nystedt S, Ramakrishnan V, Sundelin J. The proteinase-activated receptor 2 is induced by inflammatory mediators in human endothelial cells: comparison with the thrombin receptor. J Biol Chem. 1996;271:14910–14915. [PubMed]
27. Hamilton JR, Frauman AG, Cocks TM. Increased expression of protease-activated receptor-2 (PAR2) and PAR4 in human coronary artery by inflammatory stimuli unveils endothelium-dependent relaxations to PAR2 and PAR4 agonists. Circ Res. 2001;89:92–98. [PubMed]
28. Lindner J, Kahn ML, Coughlin SR, et al. Delayed onset of inflammation in protease-activated receptor- 2-deficient mice. J Immunol. 2000;165:6504–6510. [PubMed]
29. Ferrell WR, Lockhart JC, Kelso EB, et al. Essential role for proteinase-activated receptor-2 in arthritis. J Clin Invest. 2003;111:35–41. [PMC free article] [PubMed]
30. Cunningham MA, Rondeau E, Chen X, Coughlin SR, Holdsworth SR, Tipping PG. Protease-activated receptor 1 mediates thrombin-dependent, cell-mediated renal inflammation in crescentic glomerulonephritis. J Exp Med. 2000;191:455–461. [PMC free article] [PubMed]
31. Chi L, Li Y, Stehno-Bittel L, et al. Interleukin-6 production by endothelial cells via stimulation of protease activated receptors is amplified by endotoxin and tumor necrosis factor-α J Interferon Cytokine Res. 2001;21:231–240. [PubMed]
32. Parry GCN, Erlich JH, Carmeliet P, Luther T, Mackman N. Low levels of tissue factor are compatible with development and hemostasis in mice. J Clin Invest. 1998;101:560–569. [PMC free article] [PubMed]
33. Darrow AL, Fung-Leung W-P, Ye RD, et al. Biological consequences of thrombin receptor deficiency in mice. Thromb Haemost. 1996;76:860–866. [PubMed]
34. Damiano BP, Cheung W-M, Santulli RJ, et al. Cardiovascular responses mediated by protease-activated receptor-2 (PAR-2) and thrombin receptor (PAR-1) are distinguished in mice deficient in PAR-2 or PAR-1. J Pharmacol Exp Ther. 1999;288:671–678. [PubMed]
35. Fink MP, Heard SO. Laboratory models of sepsis and septic shock. J Surg Res. 1990;49:186–196. [PubMed]
36. Gertz SD, Fallon JT, Gallo R, et al. Hirudin reduces tissue factor expression in neointima after balloon injury in rabbit femoral and porcine coronary arteries. Circulation. 1998;98:580–587. [PubMed]
37. Erlich JH, Boyle EM, Jr, Labriola J, et al. Inhibition of the tissue factor-thrombin pathway limits infarct size after myocardial ischemia-reperfusion injury by reducing inflammation. Am J Pathol. 2000;157:1849–1862. [PubMed]
38. Hatton MWC, Ross B, Southward SMR, DeReske M, Richardson M. Pretreatment of rabbits with either hirudin, ancrod, or warfarin significantly reduces the immediate uptake of fibrinogen and platelets by the deendothelialized aorta wall after balloon-catheter injury in vivo. Arterioscler Thromb Vasc Biol. 1998;18:816–824. [PubMed]
39. Busso N, Peclat V, Van Ness K, et al. Exacerbation of antigen-induced arthritis in urokinase-deficient mice. J Clin Invest. 1998;102:41–50. [PMC free article] [PubMed]
40. Weiler-Guettler H, Christie PD, Beeler DL, et al. A targeted point mutation in thrombomodulin generates viable mice with a prethrombotic state. J Clin Invest. 1998;101:1983–1991. [PMC free article] [PubMed]
41. Abraham E, Reinhart K, Opal S, et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA. 2003;290:238–247. [PubMed]
42. Petersen LC. Active site-inhibited seven: mechanism of action including signal transduction. Semin Hematol. 2001;38:39–42. [PubMed]
43. Presta L, Sims P, Meng YG, et al. Generation of a humanized, high affinity anti-tissue factor antibody for use as a novel antithrombotic therapeutic. Thromb Haemost. 2001;85:379–389. [PubMed]
44. Huang M, Syed R, Stura EA, et al. The mechanism of an inhibitory antibody on TF-initiated blood coagulation revealed by the crystal structures of human tissue factor, Fab 5G9 and TF.G9 complex. J Mol Biol. 1998;275:873–894. [PubMed]
45. Gu JM, Katsuura Y, Ferrell GL, Grammas P, Esmon CT. Endotoxin and thrombin elevate rodent endothelial cell protein C receptor mRNA levels and increase receptor shedding in vivo. Blood. 2000;95:1687–1693. [PubMed]
46. Riewald M, Petrovan RJ, Donner A, Mueller BM, Ruf W. Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science. 2002;296:1880–1882. [PubMed]
47. Covic L, Misra M, Badar J, Singh C, Kuliopulos A. Pepducin-based intervention of thrombin-receptor signaling and systemic platelet activation. Nat Med. 2002;8:1161–1165. [PubMed]
48. Derian CK, Maryanoff BE, Zhang HC, Andrade-Gordon P. Therapeutic potential of protease-activated receptor-1 antagonists. Expert Opin Investig Drugs. 2003;12:209–221. [PubMed]